support@mellalta.com   +1 (304) 306-0723

T-Cell Receptor (TCR) Therapy- Executive Report 2020

$3,000.00$9,000.00

A Comprehensive Review on TCR Cell Therapy by Pipeline Analysis, Emerging Players having Innovative Portfolio, Commercial Assessment of Developmental Activities, Therapeutic Portfolio Assessment, Objective Assessment of Unmet Needs, Future Perspectives, and Technological Advancements to make informed R&D related decisions, modify therapeutic portfolio strategies, identify growth opportunities, strengthen or expand business by gaining extensive view.

Clear

Description

Mellalta, “T-Cell Receptor Therapies (TCR) – Executive Report”, provides comprehensive insights about pipeline drugs across T-Cell therapies, Deals Assessments, Collaborations & Market Opportunities.

T-cell receptor–engineered T-cell therapy and chimeric antigen receptor T-cell therapy are 2 types of adoptive T-cell therapy that genetically modify natural T cells to treat cancers. Although chimeric antigen receptor T-cell therapy has yielded remarkable efficacy for hematological malignancies of the B-cell lineages, most solid tumors fail to respond significantly to chimeric antigen receptor T cells. T-cell receptor–engineered T-cell therapy, on the other hand, has shown unprecedented promise in treating solid tumors and has attracted growing interest. Overall, TCR-T-cell therapy has been evolving rapidly and has become a promising strategy against various types of cancer, especially against solid tumors. Probably, this new approach can change the scenario of future cancer treatments.

There are 30+ active companies dealing with TCR-T Cell Therapy. Out of 30+, there are 10+ leading companies with 90+ active products in different clinical stages of development. Several major players such as Gilead Sciences, Takara Bio, Cell Medica, Immunocore, Medigene and Immatics US etc. are involved in the pipeline. Also, various academic institutes such as National Cancer Institute (NCI), National Institutes of Health (NIH) are also involved in the development of TCR-T Cell therapy. From last few years, various companies and institutes are collaborating for developing TCR-T Cell therapies. There are many emerging firms in TCR-T Cell therapy segment, which are seeking for collaborative development opportunities for the maximization of their technology and business platform.

Key Highlights of The Report

  • TCR Therapies-Companies Collaboration
  • TCR Therapies-Licensing & Acquisitions
  • TCR therapies -Funding Details
  • TCR Therapies -Company & Product Profilings
  • TCR Therapies-Products Assessments [Clinical Trials, MOA, Indications, Clinical Trials Results]

Table of Contents

1 Executive Summary 3
Key findings 3
2 T-cell receptor (TCR)-Target Background 11
Introduction 11
Structural characteristics of the TCR 11
3 TCR Therapies – Mellalta’s Analytical Perspective 14
In-depth Commercial Assessment 14
TCR Therapies – Companies collaborations, Licensing, Acquisition–Deal Value Trends 14
Year-wise Company-Company Collaborations 27
Company-Academia Collaborations 27
TCR – Acquisitions Analysis 33
TCR Licensing Deals 34
TCR – Funding Details 35
TCR Technologies for Future Pipeline development 37
Other TCR Technologies 37
TCR Target Discover Platforms 38
TCR Engineered Allogeneic T-Cells Technology 40
4 KOL and Industry Views 42
Potential of TCR therapy in lung cancer? 42
What are some of the shortcomings, in general, of immunotherapy? 42
Current limitations in immunotherapy? 42
Major challenges in developing clinical trials with this TCR technology? 43
5 Pipeline Therapeutics 44
Active Products 44
Total Products for TCR immunotherapy by Stage 45
Mid-Stage Products (Phase II) 46
Comparative Analysis 46
Early-Stage Products (Phase I and IND) 47
Comparative Analysis 47
Pre-clinical and Discovery Stage Products 49
Comparative Analysis 49
Inactive Products 51
6 Therapeutic Assessment 52
Assessment by Product Type 52
Assessment by Stage and Product type 53
Assessment by Therapy Area 54
Assessment by Stage and Therapy Area 55
7 Company Chapters 56
Gilead Sciences 56
Product Development Activities 56
KITE-439: Gilead Sciences 59
SSX-2: Gilead Sciences 60
KRAS: Gilead Sciences 62
Neoantigens: Gilead Sciences 63
KITE-718: Gilead Sciences 64
HPV-16 E6 & E7: Gilead Sciences 66
MAGE A3 TCR: Gilead Sciences 70
MAGE A3/A6 TCR: Gilead Sciences 74
Adaptimmune 77
Product Development Activities 78
ADP-A2M10: Adaptimmune 81
ADP-A2M4: Adaptimmune 83
ADP-A2AFP: Adaptimmune 89
GlaxoSmithKline 92
Product Development Activities 92
GSK 3377794: GlaxoSmithKline 94
Altor BioScience 97
Product Development Activities 97
ALT-801: Altor BioScience 99
TCR2 Therapeutics 103
Product Development Activities 103
TC-210: TCR2 Therapeutics 106
TC-220: TCR2 Therapeutics 110
TC-110: TCR2 Therapeutics 112
TC-310: TCR2 Therapeutics 115
TC-410: TCR2 Therapeutics 116
China Immunotech 117
Product Development Activities 117
EBV TCR-T: China Immunotech 117
Takara Bio 120
Product Development Activities 120
TBI 1301: Takara Bio 123
WT1-specific TCR-T cells: Takara 126
Immatics US 130
Product Development Activities 130
IMA101: Immatics 133
IMA201: Immatics US 135
IMA202: Immatics US 137
IMA203: Immatics US 139
IMA204: Immatics 141
Multiple Programs- ACTengine: Immatics 141
IMA301: Immatics US 144
IMA401: Immatics 146
IMA402: Immatics 147
IMA403: Immatics 147
Multiple Programs- TCER/DuoBody: Immatics 148
Multiple Programs- TCER/BITE: Immatics 149
BioNTech 150
Product Development Activities 150
Individualized TCR: BioNTech 154
Individualized TCR: BioNTech 155
Lion TCR 156
Product Development Activities 156
TCR Therapy for Hepatocellular carcinoma (HCC) Recurrence Post-Liver Transplantation: Lion TCR 158
TCR Redirected T Cells for the treatment of Hepatocellular carcinoma Recurrence Post-Liver Transplantation: Lion TCR 160
TCR Therapy for the treatment of HCC Recurrence Post-Liver Resection: Lion TCR 162
LioCyx: Lion TCR 163
TCR therapy for Chronic HBV Infection: Lion TCR 165
TCR therapy for EBV-related Nasopharyngeal Carcinoma: Lion TCR 166
TCR therapy for Post-Transplant Lymphoproliferative Disorders: Lion TCR 167
Cell Medica 168
Product Development Activities 168
CMD-602: Cell Medica 171
Baltaleucel-T: Cell Medica 173
Bellicum Pharmaceuticals 176
Product Development Activities 176
BPX-701: Bellicum Pharmaceuticals 178
Tmunity Therapeutics 180
Product Development Activities 180
NY-ESO1 TCR-T: Tmunity Therapeutics 182
H3.3K27M TCR: Tmunity Therapeutics 183
Immunocore 184
Product Development Activities 184
IMCgp100: Immunocore 190
IMCgp100 checkpoint combination: Immunocore 194
IMC-C103C: Immunocore 196
IMC-F106C: Immunocore 198
IMC-G107C: Immunocore 199
Additional oncology programs: Immunocore 200
Partnered oncology programs: Immunocore 201
GSK1 (IMCnyeso): Immunocore 202
Infectious Disease Programs: Immunocore 204
Autoimmune Programs: Immunocore 205
Xiangxue Life Sciences (XLifeSc) 206
Product Development Activities 206
TAEST16001: Xiangxue Life Sciences/ Athenex 208
TAEST-xx1: Xiangxue Life Sciences 211
TAEST-xx2: Xiangxue Life Sciences 212
TAEST-xx3: Xiangxue Life Sciences 213
TAEST-xx4: Xiangxue Life Sciences 214
TAEST-xx5: Xiangxue Life Sciences 215
TAEST-xx6: Xiangxue Life Sciences 216
Ziopharm 217
Product Development Activities 217
TCR Sleeping Beauty Neoantigens: Ziopharm 219
Guangzhou FineImmune Biotechnology 221
Tumor-specific TCR-T cells: Guangzhou FineImmune Biotechnology 221
Juno Therapeutics (A Celgene Company) 223
Product Development Activities 223
JTCR 016: Juno Therapeutics 225
Medigene 228
Product Development Activities 228
MDG1011: Medigene 232
MDG1021: Medigene 235
TCR Bluebird bio 1: Medigene 236
TCR Cytovant: Medigene 238
TCR-IIT: Medigene 239
Tactiva Therapeutics 240
Product Development Activities 240
T-cell cancer immunotherapies Research program: Tactiva Therapeutics (Pre-clinical) 241
Zelluna Immunotherapy 243
Product Development Activities 243
ZI-H04: Zelluna Immunotherapy 245
ZI-HX: Zelluna Immunotherapy 248
TCR-T-X: Zelluna Immunotherapy 249
ZI-NK-T01: Zelluna Immunotherapy 250
ZI-NK-HX: Zelluna Immunotherapy 251
ZI-NK-X: Zelluna Immunotherapy 251
Unum Therapeutics 253
Product Development Activities 253
ACTR707 + Rituximab: Unum Therapeutics 255
ACTR087 + rituximab: Unum Therapeutics 257
ACTR707 + Trastuzumab: Unum Therapeutics 259
ACTR087 + SEA-BCMA: Unum Therapeutics 261
Artielle ImmunoTherapeutics 263
Product Development Activities 263
RTL1000: Artielle ImmunoTherapeutics 264
AgenTus (Subsidiary of Agenus) 266
Product Development Activities 266
AgenTus NY-ESO-1 TCRs: AgenTus 267
AGENt 04002: AgenTus 270
TCRCure Biotech 274
Product Development Activities 274
HPV E6-specific TCR-T cells: TCRCure Biotech 275
Pact Pharma 277
Product Development Activities 277
NeoTCR-P1 adoptive cell therapy: Pact Pharma 279
TScan Therapeutics 285
Product Development Activities 285
TSC-100: TScan Therapeutics 286
TSC-200: TScan Therapeutics 287
Cellular Biomedicine Group 288
Product Development Activities 288
AFP TCR-T: Cellular Biomedicine Group 288
Bluebird Biosciences 290
Product Development Activities 290
MCC1 TCR: Bluebird Biosciences 290
Gritstone Oncology 292
Product Development Activities 292
Cancer Research programme: Gritstone Oncology 293
8 Future Prospective 294
9 Appendix 295
10 Unmet Needs 310
11 Disclaimer 311
12 About Mellalta 311

List of Tables

Table 3.1: TCR Therapies companies collaborations, Licensing, Acquisition – Deal Value Trends,  2013-2019 14
Table 3.2: Company-Academia Collaborations 27
Table 3.3: TCR Acquisition Analysis 33
Table 3.4: TCR Licensing Deals 34
Table 3.5: Funding Details 35
Table 3.6 Other TCR Technologies 37
Table 3.7: Technologies for Discovery of TCRs Targets 38
Table 3.8 TCR Engineered Allogeneic T-Cells Technology 40
Table 5.1: Total Products for TCR Immunotherapy by Stage 45
Table 5.2: Mid Stage Products (Phase II) 46
Table 5.3: Early Stage Products (Phase I and IND) 47
Table 5.4: Pre-clinical and Discovery Stage Products 49
Table 5.5: Inactive Products (Dormant and Discontinued) 51
Table 6.1: Assessment by Product Type 52
Table 6.2: Assessment by Stage and Product type 53
Table 6.3: Assessment by Therapy area 54
Table 6.4: Assessment by Stage and Therapy Area 55

List of Figures

Figure 2.1: TCR protein and gene structure 12
Figure 2.2: Gene rearrangement at the tr loci. 13
Figure 3.1: TCR Therapies companies collaborations, Licensing, Acquisition – Deal Value Trends,  2013-2019 14
Figure 3.2: TCR Year-wise Company-Company Collaborations, 2013-2019 27
Figure 5.1: Total Products for TCR Immunotherapy by Companies 44
Figure5.2: Total Products for TCR Immunotherapy by Stage 45
Figure5.3: Mid Stage Products (Phase II) 46
Figure5.4: Early Stage Products (Phase I and IND) 47
Figure 5.5: Pre-clinical and Discovery Stage Products 49
Figure6.1: Assessment by Product Type 52
Figure6.2: Assessment by Stage and Product type 53
Figure6.3: Assessment by Therapy area 54
Figure 6.4: Assessment by Stage and Therapy Area 55
Figure 7.1: siTCR vector technology 120
Figure 7.2: Mode of action of siTCR based therapy 121
Figure 7.3: TCR-T cell technology 157
Figure7.4: Dominant T cell receptor (dTCR) technology 170
Figure7.5: CaspaCIDe Technology 176
Figure7.6: T cell Receptor Technology 223
Figure 7.7: ImPACT Isolation Technology 277
Figure 7.8: ImPACT Isolation Technology 277
Figure 9.1: Size and composition of the pre-selection, naive and antigen-experienced repertoires. 296
Figure 9.2: Skewing of the TCR repertoire in human disease. 299
Figure 9.3: Process of TCR-engineered T cells therapy 303
Figure 9.4: TCR Signalling 305
Figure 9.5:Three typical procedures to obtain TCR sequence 306
Name
Email
Phone
Enquiry

Get In Touch

Let's keep the conversation going